Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease - Trial 2017-001309-34

Name: Clinical Trial 2017-001309-34
Creator: Vertex Pharmaceuticals Incorporated
Keywords: Cystic Fibrosis, clinical trial

Access comprehensive clinical trial information for 2017-001309-34 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently status unknown. The study focuses on Cystic Fibrosis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2017-001309-34

Trial Details

EU Clinical Trials Register • 2017-001309-34

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Study Focus

Disease/Condition

Cystic Fibrosis

Sponsor & Location

Primary Sponsor

Vertex Pharmaceuticals Incorporated

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

•Participant currently receiving invasive mechanical ventilation.

ICD-10 Classifications

Family history of congenital malformations, deformations and chromosomal abnormalities

Congenital malformations, deformations and chromosomal abnormalities

Other specified congenital malformations

Special screening examination for congenital malformations, deformations and chromosomal abnormalities

Personal history of congenital malformations, deformations and chromosomal abnormalities

Data Source

Registry

EU Clinical Trials Register

Trial ID

2017-001309-34

Type

Non-Device Trial